Get the app
US › Healthcare

Oculis Holding AG Ordinary shares (OCS)

US · Healthcare · Biotechnology

$7.49+9.66%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-10.0M
EPS
$-0.20
EPS estimate
$-0.48

EPS came in at -0.20 against a street estimate of -0.48 — a beat of 58.3%.

Key statistics

Market cap
$380.5M
Forward P/E
0.0
P/B
1.77
Book value
$4.17
EPS (TTM)
$-1.69
52-week high
$34.48
52-week low
$6.78
50-day MA
$9.42
200-day MA
$18.56
Beta
0.29

Analyst view

Analysts rate Oculis Holding AG Ordinary shares a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $37.51.

Shareholding

Insiders
3.53%
Institutions
46.93%

Largest institutional holders

FundStake
EQT Fund Management S.à r.l.11.29%
Aberdeen Group PLC3.51%
Millennium Management LLC3.32%
Pivotal bioVenture Partners Investment Advisor LLC2.45%
Citadel Advisors Llc1.60%
BRAIDWELL LP1.35%
Perceptive Advisors LLC1.31%
Saturn V Capital Management LLC1.11%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oculis Holding AG Ordinary shares — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.